Kulkarni Samarth 4
4 · CRISPR Therapeutics AG · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
CRISPR (CRSP) CEO Samarth Kulkarni Sells Shares
What Happened Samarth Kulkarni, CEO of CRISPR Therapeutics (CRSP), had 20,625 restricted stock units convert/vest on March 14, 2026 (reported as a derivative exercise/conversion). Following vesting, 10,349 shares were sold in an open-market transaction on March 16, 2026 at $48.26 per share, generating $499,443. The filing also reports the 20,625-share conversion/disposition entry tied to the RSU settlement.
Key Details
- Transaction dates: RSU conversion/vesting on 2026-03-14; open-market sale on 2026-03-16; Form 4 filed 2026-03-17 (appears timely).
- Sale: 10,349 shares at $48.26 = $499,443 (open-market; disposition code S).
- Conversion/Vesting: 20,625 shares reported as converted/exercised (code M) on 2026-03-14.
- Shares owned after transaction: Not specified in the provided filing details.
- Footnotes:
- F1: These shares remain subject to a lock-up agreement with underwriters for the issuer’s convertible senior notes due 2031.
- F2–F4: The shares stem from a March 14, 2025 RSU grant for 82,500 shares (one-quarter, 20,625, vested 3/14/2026).
- F3: The sale of 10,349 shares was mandated to cover tax withholding under the Company’s RSU Settlement Policy (i.e., not a discretionary trade).
Context This was a routine vesting and mandated sell-to-cover for tax withholding following RSU vesting (not a separate discretionary sale). The conversion/vesting and the sell-to-cover are commonly reported together; note that some or all converted shares remain subject to a lock-up per the filing.
Insider Transaction Report
- Exercise/Conversion
Common Shares
[F1][F2]2026-03-14+20,625→ 256,183 total - Sale
Common Shares
[F3]2026-03-16$48.26/sh−10,349$499,443→ 245,834 total - Exercise/Conversion
Restricted Stock Units
[F2][F1][F4]2026-03-14−20,625→ 61,875 total→ Common Shares (20,625 underlying)
Footnotes (4)
- [F1]These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
- [F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F3]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F4]This restricted stock unit award was granted on March 14, 2025 with respect to 82,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.